Pacer Advisors Inc. Purchases 83,739 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Pacer Advisors Inc. raised its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 47.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 261,483 shares of the company’s stock after purchasing an additional 83,739 shares during the period. Pacer Advisors Inc.’s holdings in Amphastar Pharmaceuticals were worth $5,122,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the business. Rice Hall James & Associates LLC increased its stake in shares of Amphastar Pharmaceuticals by 54.6% in the 1st quarter. Rice Hall James & Associates LLC now owns 187,348 shares of the company’s stock valued at $3,670,000 after purchasing an additional 66,172 shares during the last quarter. Denali Advisors LLC lifted its position in shares of Amphastar Pharmaceuticals by 56.9% during the 4th quarter. Denali Advisors LLC now owns 211,765 shares of the company’s stock worth $5,671,000 after buying an additional 76,765 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Amphastar Pharmaceuticals by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock worth $39,726,000 after buying an additional 228,262 shares during the last quarter. Bridge City Capital LLC boosted its stake in Amphastar Pharmaceuticals by 72.8% in the fourth quarter. Bridge City Capital LLC now owns 235,485 shares of the company’s stock valued at $6,306,000 after buying an additional 99,227 shares in the last quarter. Finally, TD Asset Management Inc boosted its stake in Amphastar Pharmaceuticals by 1.6% in the fourth quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock valued at $52,571,000 after buying an additional 31,160 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH opened at $20.22 on Thursday. Amphastar Pharmaceuticals, Inc. has a 12-month low of $16.65 and a 12-month high of $31.26. The business has a 50-day simple moving average of $19.62 and a two-hundred day simple moving average of $21.44. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79. The stock has a market cap of $891.41 million, a PE ratio of 12.18, a PEG ratio of 4.20 and a beta of 0.89.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The firm had revenue of $171.17 million for the quarter, compared to analyst estimates of $173.46 million. Amphastar Pharmaceuticals had a net margin of 11.00% and a return on equity of 15.12%. Analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on AMPH shares. Barclays lowered their target price on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating for the company in a research note on Wednesday, June 3rd. Zacks Research upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $19.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Thursday, May 14th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Six analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $22.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.